This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Expand Energy Q2 Earnings & Revenues Miss Estimates, Both Increase Y/Y
by Zacks Equity Research
EXE's Q2 2025 earnings and revenues miss estimates, but increase year over year, driven by strong production and higher natural gas price realization.
Liberty Energy Q2 Earnings Miss, Sales Beat Estimates, Both Fall Y/Y
by Zacks Equity Research
LBRT's second-quarter earnings miss estimates and fall year over year, due to increased macroeconomic uncertainty and energy sector volatility.
Core Laboratories Q2 Earnings Beat Estimates, Expenses Increase Y/Y
by Zacks Equity Research
CLB's second-quarter earnings beat estimates. However, it declined year over year due to the underperformance of the Reservoir Description segment.
Core Laboratories (CLB) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of +5.56% and +1.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Watch These 4 Energy Stocks for Q2 Earnings: Beat or Miss?
by Turjya Saha
Here's a preview of what to expect from energy stocks EQNR, CLB, OII and PTEN ahead of their quarterly earnings reports, set to be released tomorrow.
Core Laboratories to Post Q2 Earnings: Key Metrics to Watch
by Zacks Equity Research
CLB's second-quarter revenues are likely to have declined from the year-ago period's level due to weak segment revenues.
Do Options Traders Know Something About Core Laboratories Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CLB stock based on the movements in the options market lately.
Core Lab Stock Plunges 22% in Six Months: Time to Hold or Sell?
by Zacks Equity Research
CLB struggles with declining revenues, geopolitical risks, margin compression and weak U.S. demand, creating uncertainty around growth and profitability prospects.
SLB Outperforms Industry in 6 Months: What Investors Should Know
by Zacks Equity Research
SLB shares have dropped 6.5% over the past six months, narrower than the declines seen in peers and the broader sector, with bullish signals and strong global growth drivers.
Why Is Core Laboratories (CLB) Down 5.9% Since Last Earnings Report?
by Zacks Equity Research
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Core Laboratories Down 30% YTD: Should You Hold or Sell the Stock?
by Zacks Equity Research
CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability.
New Strong Sell Stocks for May 14th
by Zacks Equity Research
AMTB, CLB and EXPI have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2025.
Williams Companies Q1 Earnings Beat Estimates, Expenses Rise Y/Y
by Zacks Equity Research
WMB's Q1 earnings show that the Transmission & Gulf of America, Northeast G&P and West segments outperform, but Gas & NGL Marketing Services lags.
Magnolia Q1 Earnings & Revenues Beat Estimates, Expenses Increase Y/Y
by Zacks Equity Research
MGY's earnings beat estimates and revenues increase year over year, driven by production growth and higher revenues from natural gas and natural gas liquids.
ProPetro Q1 Earnings Beat Estimates, Revenues Decrease Y/Y
by Zacks Equity Research
PUMP's first-quarter 2025 earnings beat the Zacks Consensus Estimate, driven by a year-over-year decline in costs and expenses.
Expand Energy Q1 Earnings Beat Estimates, Revenues Increase YoY
by Zacks Equity Research
EXE's Q1 2025 results show earnings and revenue outperformance, driven by strong production and higher price realization.
Core Laboratories Q1 Earnings Miss Estimates, Expenses Increase YoY
by Zacks Equity Research
CLB's first-quarter earnings miss estimates due to the underperformance of the Reservoir Description segment.
New Strong Sell Stocks for April 24th
by Zacks Equity Research
AMPY, CARS and CLB have been added to the Zacks Rank #5 (Strong Sell) List on April 24, 2025.
Core Laboratories (CLB) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of -6.67% and 0.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Halliburton (HAL) Q1 Earnings Match Estimates
by Zacks Equity Research
Halliburton (HAL) delivered earnings and revenue surprises of 0% and 3.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Core Laboratories to Post Q1 Earnings: Key Metrics to Watch
by Zacks Equity Research
CLB's first-quarter revenues are likely to have declined from the year-ago period's level. However, cost reductions are expected to have provided modest relief.
Schlumberger (SLB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Schlumberger (SLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How to Play Core Labs Stock Ahead of Its Q1 Earnings Release
by Zacks Equity Research
CLB faces declining revenues, weak margins, geopolitical disruptions and inventory issues, with low dividend yield and overvaluation increasing investor caution.
Oceaneering International (OII) Surges 13.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Oceaneering International (OII) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.